Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
Fiche publication
Date publication
février 2024
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LEROUX Agnès, Pr MARCHAL Frédéric
Tous les auteurs :
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Quenet F, Marchal F, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V,
Lien Pubmed
Résumé
Ovarian pseudomyxoma peritonei (OPMP) are rare, without well-defined therapeutic guidelines. We aimed to evaluate cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat OPMP.
Mots clés
Cytoreduction, HIPEC, Mucinous tumor from teratoma, Ovarian carcinoma, Ovarian pseudomyxoma, Peritoneal pseudomyxoma
Référence
Ann Surg Oncol. 2024 02 10;: